$ELAB
PMGC Holdings Inc. Stock $elab

$elab Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000121390024043568 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$605.5K	$614.6K	$698.6K
YoY Change	89.23%	338.97%
Cost Of Revenue	$166.3K	$168.9K	$236.9K
YoY Change	51.16%	322.28%
Gross Profit	$439.3K	$445.7K	$461.7K
YoY Change	109.17%	345.65%
Gross Profit Margin	72.54%	72.52%	66.09%
Selling, General & Admin	$1.385M	$1.272M	$1.411M
YoY Change	23.7%	47.87%
% of Gross Profit	315.41%	285.35%	305.63%
Research & Development	$52.39K	$103.2K	$122.5K
YoY Change	-59.7%	28.99%
% of Gross Profit	11.93%	23.16%	26.53%
Depreciation & Amortization	$24.77K	$21.19K	$2.910K
YoY Change	147.7%		-70.9%
% of Gross Profit	5.64%	4.75%	0.63%
Operating Expenses	$1.848M	$2.129M	$1.536M
YoY Change	46.66%	124.12%
Operating Profit	-$1.409M	-$1.683M	-$1.074M
YoY Change	34.15%	98.05%
Interest Expense	-$4.120K	$251.0K	$366.5K
YoY Change	-98.21%	-209.11%
% of Operating Profit
Other Income/Expense, Net	$0.00	$34.72K	$32.19K
YoY Change
Pretax Income	-$1.412M	-$1.397M	-$1.158M
YoY Change	10.35%	29.38%
Income Tax
% Of Pretax Income
Net Earnings	-$1.412M	-$1.397M	-$1.158M
YoY Change	10.35%	29.38%
Net Earnings / Revenue	-233.27%	-227.36%	-165.75%
Basic Earnings Per Share	-$0.08	-$0.08
Diluted Earnings Per Share	-$0.08	-$0.08	-$0.07
COMMON SHARES
Basic Shares Outstanding	18.89M shares	17.33M shares	17.33M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$100.0K	$943.8K	$3.327M
YoY Change	-83.33%
Cash & Equivalents	$100.0K	$943.8K	$3.327M
Short-Term Investments
Other Short-Term Assets	$923.4K	$1.198M	$1.061M
YoY Change	171.6%
Inventory	$978.5K	$945.1K	$495.7K
Prepaid Expenses
Receivables	$20.71K	$48.59K	$33.09K
Other Receivables	$8.360K	$5.620K	$3.070K
Total Short-Term Assets	$2.031M	$3.141M	$4.919M
YoY Change	40.08%		-99.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$55.75K	$59.00K	$259.7K
YoY Change	-80.09%		-99.51%
Goodwill
YoY Change
Intangibles	$2.845M	$843.5K	$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.77K	$10.77K	$10.77K
YoY Change	7.7%
Total Long-Term Assets	$3.049M	$1.086M	$270.5K
YoY Change	951.42%		-99.92%
TOTAL ASSETS
Total Short-Term Assets	$2.031M	$3.141M	$4.919M
Total Long-Term Assets	$3.049M	$1.086M	$270.5K
Total Assets	$5.080M	$4.227M	$5.190M
YoY Change	191.97%		-99.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.141M	$395.2K	$596.2K
YoY Change	111.23%
Accrued Expenses	$40.81K	$133.6K	$218.2K
YoY Change	-80.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.935M	$1.222M	$1.297M
YoY Change	24.05%		-99.78%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$505.4K	$518.1K	$65.49K
YoY Change	359.42%
Total Long-Term Liabilities	$505.4K	$518.1K	$65.49K
YoY Change	359.42%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.935M	$1.222M	$1.297M
Total Long-Term Liabilities	$505.4K	$518.1K	$65.49K
Total Liabilities	$2.441M	$1.740M	$1.363M
YoY Change	45.27%		-99.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$9.834M	-$8.421M	-$7.024M
YoY Change			-99.74%
Common Stock	$12.47M	$10.91M	$1.733K
YoY Change		-70.92%	-99.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.640M	$2.486M	$3.827M
YoY Change
Total Liabilities & Shareholders Equity	$5.080M	$4.227M	$5.190M
YoY Change	191.97%		-99.73%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$1.412M	-$1.397M	-$1.158M
YoY Change	10.35%	29.38%
Depreciation, Depletion And Amortization	$24.77K	$21.19K	$2.910K
YoY Change	147.7%		-70.9%
Cash From Operating Activities	-$780.7K	-$2.324M	-$2.388M
YoY Change	-52.69%	162.46%	117.1%
INVESTING ACTIVITIES
Capital Expenditures	$62.32K	$9.160K	$0.00
YoY Change	523.2%	-18.15%	-100.0%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	-$62.32K	-$59.16K	$0.00
YoY Change	523.2%	428.64%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000		5.238M
YoY Change	-100.0%		177.13%
NET CHANGE
Cash From Operating Activities	-780.7K	-$2.324M	-2.388M
Cash From Investing Activities	-62.32K	-$59.16K	0.000
Cash From Financing Activities	0.000		5.238M
Net Change In Cash	-843.0K	-$2.383M	2.850M
YoY Change	53.27%	2085.17%	274.95%
FREE CASH FLOW
Cash From Operating Activities	-$780.7K	-$2.324M	-$2.388M
Capital Expenditures	$62.32K	$9.160K	$0.00
Free Cash Flow	-$843.0K	-$2.333M	-$2.388M
YoY Change	-49.22%	160.2%	111.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	943797	usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	120 Newport Center Drive
CY2024Q1	dei	Entity Address Address Line3 EntityAddressAddressLine3	Suite 250
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Newport Beach
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92660
CY2024Q1	dei	City Area Code CityAreaCode	(866)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	794-4940
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18892115	shares
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3326851	usd
CY2024Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	54205	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	36161	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1197687	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1060765	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	945064	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	495667	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	3140753	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4919444	usd
CY2024Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10773	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10773	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59003	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	53119	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	843505	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	172562	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	206582	usd
CY2024Q1	us-gaap	Assets Assets	4226596	usd
CY2023Q4	us-gaap	Assets Assets	5189918	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	528822	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	669375	usd
CY2024Q1	us-gaap	Customer Deposits Current CustomerDepositsCurrent	35148	usd
CY2023Q4	us-gaap	Customer Deposits Current CustomerDepositsCurrent	36693	usd
CY2024Q1	us-gaap	Loans Payable Current LoansPayableCurrent	338889	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	149208	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	145000	usd
CY2024Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	94219	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	369158	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1222122	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1297353	usd
CY2024Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	491557	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26571	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	65489	usd
CY2024Q1	us-gaap	Liabilities Liabilities	1740250	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1362842	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17329615	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17329615	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17329615	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17329615	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	1733	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1733	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10904370	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10849031	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1383	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	202	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8421140	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7023890	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	2486346	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3827076	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4226596	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5189918	usd
CY2024Q1	us-gaap	Revenues Revenues	614563	usd
CY2023Q1	us-gaap	Revenues Revenues	142820	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	168911	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	44433	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	445652	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	98387	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	20331	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2497	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	393038	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	102676	usd
CY2024Q1	us-gaap	Management Fee Expense ManagementFeeExpense	396126	usd
CY2023Q1	us-gaap	Management Fee Expense ManagementFeeExpense	83964	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	878608	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	434059	usd
CY2024Q1	us-gaap	Professional Fees ProfessionalFees	179922	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	137797	usd
CY2024Q1	elab	Investor Relations InvestorRelations	98245	usd
CY2023Q1	elab	Investor Relations InvestorRelations	38268	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	103194	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	83741	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-541	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-259	usd
CY2024Q1	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	59108	usd
CY2023Q1	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	61515	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	2129113	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	944776	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1683461	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-846389	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-274939	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	236778	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	86	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	5107	usd
CY2024Q1	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	23537	usd
CY2023Q1	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	2636	usd
CY2024Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	34723	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1397250	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1080696	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1181	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	113	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1396069	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1080583	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.081
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.111
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17329615	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9707364	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1131310	usd
CY2023Q1	elab	Stock Issued During Period Value Private Placement StockIssuedDuringPeriodValuePrivatePlacement	750000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	37500	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	75161	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1080696	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	113	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	913388	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3827076	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	55339	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1397250	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	1181	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	2486346	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1397250	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1080696	usd
CY2024Q1	us-gaap	Depreciation Depreciation	21188	usd
CY2023Q1	us-gaap	Depreciation Depreciation	2912	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	55339	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	75161	usd
CY2024Q1	us-gaap	Straight Line Rent StraightLineRent	690	usd
CY2023Q1	us-gaap	Straight Line Rent StraightLineRent	689	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-274939	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	236778	usd
CY2024Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	18994	usd
CY2024Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	18119	usd
CY2023Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	33253	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	136951	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	222404	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	449397	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	83363	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-140698	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	130484	usd
CY2024Q1	us-gaap	Increase Decrease In Customer Deposits IncreaseDecreaseInCustomerDeposits	-1545	usd
CY2023Q1	us-gaap	Increase Decrease In Customer Deposits IncreaseDecreaseInCustomerDeposits	59564	usd
CY2023Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	30000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2324068	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-885506	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9160	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11191	usd
CY2024Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	50000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-59160	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11191	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	37500	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	750000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	787500	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	174	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	141	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2383054	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-109056	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3326851	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1154901	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	943797	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1045845	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	4542	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	2636	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.5in"><b>1.</b></td><td style="text-align: justify"><b>Organization and nature of operations</b></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Elevai Labs Inc. (“Elevai”) was incorporated under the laws of the State of Delaware on June 9, 2020. Elevai and its 100% owned subsidiary, Elevai Research Inc, are collectively referred to in these unaudited condensed consolidated financial statements as “the Company”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company is a skincare development company engaged in the design, manufacture, and marketing of skincare products in the skincare industry. The Company’s principal activities are developing and manufacturing skincare products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On April 29, 2024, Elevai Skincare Inc. (“Skincare”) and Elevai BioSciences Inc. (“BioSciences”) were incorporated under the laws of the state of Delaware. Elevai is the sole shareholder of Skincare and BioSciences. The purpose of Skincare is to operate the Company’s existing business. While the purpose of BioSciences is to develop the Company’s 2 drug candidates, EL-22, a clinical stage engineered probiotic expressing myostatin, and EL-32, a preclinical engineered probiotic expressing dual myostatin and activin-A. Effective May 1, 2024, Elevai transferred its operating assets and liabilities relating to its skincare business to Skincare in exchange for common shares of Skincare.</p>
CY2024Q1	elab	Net Working Capital NetWorkingCapital	1918631	usd
CY2023Q4	elab	Net Working Capital NetWorkingCapital	3622091	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8421140	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7023890	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1397250	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1080696	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2324068	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-885506	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to revenue recognition, the collectability of receivables, valuation of inventory, fair value of derivative liabilities and stock options, useful lives and recoverability of long-lived assets, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from those estimates. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the unaudited condensed consolidated financial statements in the period they are determined.</p>
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10773	usd
CY2024Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10773	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10773	usd
CY2024Q1	elab	Trade Receivable TradeReceivable	48590	usd
CY2023Q4	elab	Trade Receivable TradeReceivable	33089	usd
CY2024Q1	elab	Sales Taxes Receivable SalesTaxesReceivable	5615	usd
CY2023Q4	elab	Sales Taxes Receivable SalesTaxesReceivable	3072	usd
CY2024Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	54205	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	36161	usd
CY2024Q1	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	1179438	usd
CY2023Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	957645	usd
CY2024Q1	us-gaap	Deposit Assets DepositAssets	29022	usd
CY2023Q4	us-gaap	Deposit Assets DepositAssets	113893	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1208460	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1071538	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1197687	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1060765	usd
CY2024Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10773	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	331371	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	279514	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	283780	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	147906	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	329913	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	68247	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	945064	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	495667	usd
CY2024Q1	us-gaap	Cost Of Goods Sold Sales Type Lease CostOfGoodsSoldSalesTypeLease	80907	usd
CY2023Q1	us-gaap	Cost Of Goods Sold Sales Type Lease CostOfGoodsSoldSalesTypeLease	19750	usd
CY2024Q1	us-gaap	Marketing Expense MarketingExpense	48989	usd
CY2023Q1	us-gaap	Marketing Expense MarketingExpense	21068	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	61640	usd
CY2023	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	11191	usd
CY2023	elab	Property Plant And Equipment Foreign Currency Translation PropertyPlantAndEquipmentForeignCurrencyTranslation	61	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	72892	usd
CY2024Q1	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	9160	usd
CY2024Q1	elab	Property Plant And Equipment Foreign Currency Translation PropertyPlantAndEquipmentForeignCurrencyTranslation	-59	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	81993	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8105	usd
CY2023	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease	11649	usd
CY2023	elab	Equipment Foreign Currency Translation Accumulated Depreciation EquipmentForeignCurrencyTranslationAccumulatedDepreciation	19	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19773	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease	3239	usd
CY2024Q1	elab	Equipment Foreign Currency Translation Accumulated Depreciation EquipmentForeignCurrencyTranslationAccumulatedDepreciation	-22	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	22990	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	53119	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	188675	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	12896	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	175779	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	149208	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26571	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.115	pure
CY2023Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.08	pure
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M1D
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59003	usd
CY2024Q1	us-gaap	Capitalized Costs Accumulated Depreciation Depletion Amortization And Valuation Allowance For Relating To Oil And Gas Producing Activities CapitalizedCostsAccumulatedDepreciationDepletionAmortizationAndValuationAllowanceForRelatingToOilAndGasProducingActivities	853	usd
CY2023Q1	us-gaap	Capitalized Costs Accumulated Depreciation Depletion Amortization And Valuation Allowance For Relating To Oil And Gas Producing Activities CapitalizedCostsAccumulatedDepreciationDepletionAmortizationAndValuationAllowanceForRelatingToOilAndGasProducingActivities	412	usd
CY2024Q1	elab	Purchase Price PurchasePrice	1000000	usd
CY2024Q1	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	600000	usd
CY2023Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	47986	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	39741	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	31630	usd
CY2024Q1	us-gaap	Defined Benefit Plan Administration Expenses DefinedBenefitPlanAdministrationExpenses	25975	usd
CY2023Q1	us-gaap	Defined Benefit Plan Administration Expenses DefinedBenefitPlanAdministrationExpenses	22176	usd
CY2024Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	9453	usd
CY2023Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	7299	usd
CY2024Q1	us-gaap	Capitalized Costs Of Unproved Properties Excluded From Amortization CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortization	4313	usd
CY2023Q1	us-gaap	Capitalized Costs Of Unproved Properties Excluded From Amortization CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortization	2155	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	39741	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	31630	usd
CY2024Q1	us-gaap	Security Deposit SecurityDeposit	10773	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	10773	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	121291	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	67384	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y5M1D
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	395249	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	596147	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	133573	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	73228	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	528822	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	669375	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	950000	usd
CY2024Q1	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	950000	usd
CY2024Q1	elab	Consideration Payable Discount ConsiderationPayableDiscount	138548	usd
CY2022Q3	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	231828	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.01
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Expiration Date ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate	2028-11-21
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y5M15D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y8M15D
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	231828	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Expiration Date ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate	2027-04-27
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17329615	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17329615	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17329615	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17329615	shares
CY2023Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	62500	shares
CY2023Q1	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	0.6
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	37500	usd
CY2023Q1	elab	Purchase Of Common Stock Warrants PurchaseOfCommonStockWarrants	250000	shares
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	750000	usd
CY2024Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P2Y6M21D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	12500	shares
CY2024Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2024Q1	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	5
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	16178	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	80000	shares
CY2024Q1	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	1
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	52845	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	10000	shares
CY2023Q1	us-gaap	Equity Security Fv Ni Contractual Sale Restriction Remaining Period EquitySecurityFvNiContractualSaleRestrictionRemainingPeriod	P10Y
CY2023Q1	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	5
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	10767	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0	pure
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55339	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	75161	usd
CY2024Q1	elab	Percentage Of Authority Control PercentageOfAuthorityControl	0.10	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	80000	shares
CY2024Q1	us-gaap	Deferred Compensation Arrangement With Individual Maximum Contractual Term1 DeferredCompensationArrangementWithIndividualMaximumContractualTerm1	P10Y
CY2024Q1	us-gaap	Stock Issued1 StockIssued1	45986	usd
CY2024Q1	elab	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Right Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightPercentage	0.25	pure
CY2024Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	22276	usd
CY2023Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	46986	usd
CY2024Q1	elab	Fair Value Of Stock Options Granted FairValueOfStockOptionsGranted	1049898	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	58333	shares
CY2024Q1	us-gaap	Interest Bearing Deposit Liabilities InterestBearingDepositLiabilities	22195	usd
CY2023Q4	us-gaap	Interest Bearing Deposit Liabilities InterestBearingDepositLiabilities	22455	usd
CY2024Q1	elab	Customer Representing Revenue CustomerRepresentingRevenue	67500	usd
CY2024Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	25500	usd
CY2024Q2	us-gaap	Payments For Fees PaymentsForFees	400000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	elab	Non Rule10b51 Arrangement Modified NonRule10b51ArrangementModified	false
CY2024Q1	elab	Rule10b51 Arrangement Modified Rule10b51ArrangementModified	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.081
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.111
CY2023Q1	us-gaap	Other Noncash Expense OtherNoncashExpense		usd
CY2024Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties		usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables		usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables		usd
CY2024Q1	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses		usd
CY2023	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses		usd
CY2024Q1	us-gaap	Inventory Net Of Allowances Customer Advances And Progress Billings InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings		usd
CY2023Q4	us-gaap	Inventory Net Of Allowances Customer Advances And Progress Billings InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings		usd
CY2023	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals		usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm
CY2023	us-gaap	Legal Fees LegalFees		usd
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001840563

Files In Submission

Name	View Source	Status
0001213900-24-043568-index-headers.html	Edgar Link	pending
0001213900-24-043568-index.html	Edgar Link	pending
0001213900-24-043568.txt	Edgar Link	pending
0001213900-24-043568-xbrl.zip	Edgar Link	pending
ea0205793-10q_elevai.htm	Edgar Link	pending
ea020579301ex31-1_elevai.htm	Edgar Link	pending
ea020579301ex31-2_elevai.htm	Edgar Link	pending
ea020579301ex32-1_elevai.htm	Edgar Link	pending
elab-20240331.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
elab-20240331_lab.xml	Edgar Link	unprocessable
elab-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ea0205793-10q_elevai_htm.xml	Edgar Link	completed
elab-20240331_cal.xml	Edgar Link	unprocessable
elab-20240331_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELAB
PMGC Holdings Inc. Stock $elab

2024 Q2 Form 10-Q Financial Statement

#000121390024043568 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELAB PMGC Holdings Inc. Stock $elab

2024 Q2 Form 10-Q Financial Statement

#000121390024043568 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELAB
PMGC Holdings Inc. Stock $elab